Clinical and biological implications of driver mutations in myelodysplastic syndromes-Reference-Cited by-同舟云学术

Clinical and biological implications of driver mutations in myelodysplastic syndromes

Published:2013-11-21 Issue:22 Volume:122 Page:3616-3627
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Papaemmanuil Elli¹,Gerstung Moritz¹,Malcovati Luca²,Tauro Sudhir³,Gundem Gunes¹,Van Loo Peter¹⁴⁵,Yoon Chris J.¹,Ellis Peter¹,Wedge David C.¹,Pellagatti Andrea⁶,Shlien Adam¹,Groves Michael John³,Forbes Simon A.¹,Raine Keiran¹,Hinton Jon¹,Mudie Laura J.¹,McLaren Stuart¹,Hardy Claire¹,Latimer Calli¹,Della Porta Matteo G.²,O’Meara Sarah¹,Ambaglio Ilaria²,Galli Anna²,Butler Adam P.¹,Walldin Gunilla⁷,Teague Jon W.¹,Quek Lynn⁸,Sternberg Alex⁸⁹,Gambacorti-Passerini Carlo¹⁰,Cross Nicholas C. P.¹¹,Green Anthony R.¹²¹³,Boultwood Jacqueline⁶,Vyas Paresh⁷,Hellstrom-Lindberg Eva⁷,Bowen David¹⁴,Cazzola Mario²,Stratton Michael R.¹,Campbell Peter J.¹¹²¹³

Affiliation:

1. Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom;

2. Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, University of Pavia, Pavia, Italy;

3. Division of Medical Sciences, University of Dundee, Dundee, United Kingdom;

4. Center for the Biology of Disease, Vlaams Instituut voor Biotechnologie, Leuven, Belgium;

5. Department of Human Genetics, Katholieke Universiteit Leuven, Leuven, Belgium;

6. Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, United Kingdom;

7. Department of Haematology, Karolinska Institute, Stockholm, Sweden;

8. Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom;

9. Department of Haematology, Great Western Hospital, Swindon, United Kingdom;

10. Department of Haematology, University of Milan Bicocca, Milan, Italy;

11. Faculty of Medicine, University of Southampton, Southampton, United Kingdom;

12. Department of Haematology, University of Cambridge, Cambridge, United Kingdom;

13. Department of Haematology, Addenbrooke’s Hospital, Cambridge, United Kingdom; and

14. St. James Institute of Oncology, St. James Hospital, Leeds, United Kingdom

Abstract

Key Points MDS is characterized by mutations in >40 genes, a complex structure of gene-gene interactions and extensive subclonal diversification. The total number of oncogenic mutations and early detection of subclonal mutations are significant prognostic variables in MDS.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/22/3616/1371826/3616.pdf

Reference48 articles.

1. Cancer genome landscapes.;Vogelstein;Science,2013

2. Genomics-driven oncology: framework for an emerging paradigm.;Garraway;J Clin Oncol,2013

3. Myelodysplastic syndromes.;Tefferi;N Engl J Med,2009

4. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification.;Font;Ann Hematol,2013

5. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.;Abdel-Wahab;Leukemia,2011

Cited by 1538 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How we diagnose Myelodysplastic syndromes;Frontiers in Oncology;2024-09-13

2. Untangling the loops of STAG2 mutations in myelodysplastic syndrome;Leukemia & Lymphoma;2024-09-12

3. Case report: Development of clonal hematologic disorders from inherited bone marrow failure;Frontiers in Oncology;2024-09-09

4. Identification of novel myelodysplastic syndromes prognostic subgroups by integration of inflammation, cell-type composition, and immune signatures in the bone marrow;eLife;2024-09-05

5. Identification of novel myelodysplastic syndromes prognostic subgroups by integration of inflammation, cell-type composition, and immune signatures in the bone marrow;eLife;2024-09-05